Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for I-Mab Sponsored ADR (IMAB : NSDQ)
 
 • Company Description   
I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.

Number of Employees: 32

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.42 Daily Weekly Monthly
20 Day Moving Average: 1,177,170 shares
Shares Outstanding: 81.66 (millions)
Market Capitalization: $197.62 (millions)
Beta: 1.39
52 Week High: $3.08
52 Week Low: $0.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 89.06% 80.87%
12 Week 290.32% 218.44%
Year To Date 184.71% 169.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2440 RESEARCH BLVD SUITE 400
-
ROCKVILLE,MD 20850
USA
ph: 301-670-2800
fax: -
ir@imabbio.com https://ir.i-mabbiopharma.com
 
 • General Corporate Information   
Officers
Xi-Yong (Sean) Fu - Chief Executive Officer and Director
Wei Fu - Chairperson of the Board of Directors
Joseph Skelton - Chief Financial Officer
Lielie Zhang - Director
Chun Kwok Alan Au - Director

Peer Information
I-Mab Sponsored ADR (CORR.)
I-Mab Sponsored ADR (RSPI)
I-Mab Sponsored ADR (CGXP)
I-Mab Sponsored ADR (BGEN)
I-Mab Sponsored ADR (GTBP)
I-Mab Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 44975P103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/27/25
Share - Related Items
Shares Outstanding: 81.66
Most Recent Split Date: (:1)
Beta: 1.39
Market Capitalization: $197.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/27/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.99
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -19.81
12/31/24 - -29.62
ROA
06/30/25 - -
03/31/25 - -18.63
12/31/24 - -27.78
Current Ratio
06/30/25 - -
03/31/25 - 22.35
12/31/24 - 20.90
Quick Ratio
06/30/25 - -
03/31/25 - 22.35
12/31/24 - 20.90
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.43
12/31/24 - 2.47
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©